<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551109</url>
  </required_header>
  <id_info>
    <org_study_id>ME1-1</org_study_id>
    <secondary_id>EudraCT number: 2007-002740-16</secondary_id>
    <nct_id>NCT00551109</nct_id>
  </id_info>
  <brief_title>SA4503 8-Week Study in Major Depressive Disorder (MDD)</brief_title>
  <official_title>A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment With SA4503, Once Daily for 8 Weeks, in Subjects With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M's Science Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M's Science Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of SA4503 compared to placebo in the
      treatment of subjects with major depressive disorder (MDD). Secondary, to evaluate the safety
      of SA4503 compared to placebo in subjects with MDD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further study details as provided by M's Science Corporation:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Åsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SA4503</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SA4503</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo, oral administration, once daily for 8 weeks</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SA4503 Low</intervention_name>
    <description>Low dose, oral administration, once daily for 8 weeks</description>
    <arm_group_label>A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SA4503 High</intervention_name>
    <description>High dose, oral administration, once daily for 8 weeks</description>
    <arm_group_label>A2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the ages of 18 and 65 (inclusive)

          -  Diagnosis of MDD according to the Diagnostic and Statistical Manual of Mental
             Disorders (DSM)-IV criteria and a shortened MINI evaluation

          -  HAM-D17 score of &gt;/= 21 and a severity score of at least 2 for Item 1 (depressed mood)
             at both Screening and Baseline

          -  Current depressive episode of at least 3 months duration, and significant depressed
             mood and anhedonia in the 4 weeks prior to Screening.

        Exclusion Criteria:

          -  Subjects who have received fluoxetine within 1 month prior to Baseline or any other
             antidepressant within 2 weeks prior to Baseline, or any unlicensed medication within 1
             month before Screening

          -  Subjects who require psychotropic medication other than the study medication

          -  Subjects who started psychotherapy within 4 months prior to Screening

          -  Subjects who currently (i.e., in the month prior to Screening) meet DSM-IV criteria
             for bipolar syndrome or psychotic depression or severe somatoform or eating disorders

          -  Subjects who have a primary diagnosis of anxiety

          -  Subjects who regularly use sleeping medication more than 3 times per week

          -  Subjects who have major psychiatric or neurologic disorders other than MDD

          -  Subjects with depression secondary to stroke, cancer, or other severe medical illness

          -  Subjects who have a history of alcohol or substance dependence(within 1 year prior to
             Screening)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Björn Appelberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>December 17, 2008</last_update_submitted>
  <last_update_submitted_qc>December 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Kazunori Yoshikawa</name_title>
    <organization>M's Science Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SA 4503</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

